探索Vessilen®在治疗膀疼痛综合征/间歇性囊炎中的有效性:一项前性研究
Mariachiara Palucci1, Marta Barba1, Alice Cola1
1Department of Gynecology, Fondazione IRCCS San Gerardo dei Tintori, University of Milano-Bicocca, 20900 Monza, Italy.
Healthcare (Basel, Switzerland)
|June 13, 2025
概括
膀疼痛综合征 (BPS) /间歇性囊炎 (IC) 的新配方Vessilen在试点研究中显著降低了疼痛和尿路症状. 80%的患者报告说情况有所改善,这表明慢性膀疾病有前途的新疗法.
科学领域:
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 药理学 药理学是指药理学的学科.
- 炎症研究 炎症研究
背景情况:
- 膀疼痛综合征 (BPS) /间歇性囊炎 (IC) 是一种慢性疾病,具有衰弱症状和不明原因.
- 目前治疗BPS/IC的疗法效果有限,需要新的治疗策略.
- 肠道治疗是常见的,但需要新的配方来解决炎症和疼痛途径.
研究的目的:
- 在IC/BPS患者中评估静脉注射Vessilen (阿德尔米德罗尔+氨酸) 的抗炎和减轻疼痛作用.
- 评估Vessilen对患者报告的下尿路症状和整体幸福感的影响.
- 探索Vessilen作为慢性炎症膀疾病的潜在创新治疗方法.
主要方法:
- 一项试点研究涉及25名IC/BPS或其他膀疾病的患者.
- 患者每周接受六次Vessilen的静脉灌注.
- 在治疗前和治疗后使用视觉模拟量表 (VAS),ICIQ-FLUTS和患者全球印象 (PGI) 量表来评估症状严重程度.
主要成果:
- 观察到膀症状显著减少,ICIQ-FLUTS评分从89.3降至61.3 (p=0.021) 和VAS评分从4.4降至2.6 (p<0.001).
- 80%的患者报告了基于PGI-I规模 (得分≤3) 的整体症状改善.
- 治疗耐受性良好,在这个试点研究的背景下没有报告任何重大不良事件.
结论:
- 在IC/BPS患者中,静脉内Vessilen表现出显著的抗炎和抗受体特性.
- 维西林代表了一种有前途的,创新的治疗选择,用于治疗慢性炎症性膀疾病.
- 需要进一步的研究来证实这些发现在更大的,对BPS/IC治疗的受控试验中.
相关概念视频
Drugs for Treatment of Diarrhea-Predominant IBS
153
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
153
Drugs for Treatment of Constipation-Predominant IBS
146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
138
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
138
Antihypertensive Drugs: Vasodilators
492
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
492


